Mouse Anti-Human VEGF-D

Slide this table

Cat-Nr.101-M66
Size100 µg
Price380 €
CategoryMonoclonal Antibody
Clone Nr.(#7E79)
IsotypeIgG2
Species ReactivityHuman
Formulationlyophilized
BufferPBS
ReconstitutionCentrifuge vial prior to opening. Reconstitute the antibody with 500 µl sterile PBS and the final concentration is 200 µg/ml.
Stability and StorageLyophilized samples are stable for 2 years from date of receipt when stored at -20°C. Reconstituted antibody can be aliquoted and stored frozen at < -20°C for at least six months without detectable loss of activity.
PreparationThis antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse) immunized with recombinant human VEGF-D recombinant protein. The IgG2 fraction of culture supernatant was purified by Protein G affinity chromatography.
Antigenrecombinant human VEGF-D
ApplicationWB, IHC (P)
Synonymsvascular endothelial growth factor D; FIGF; VEGFD; VEGF-D
DescriptionVEGF-D, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-D is highly expressed in the lung, heart, small intestine and fetal lung, and at lower levels in the skeletal muscle, colon, and pancreas. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-D may play a role in the formation of the venous and lymphatic vascular systems. It also participates in the growth and maintenance of differentiated lymphatic endothelium in adults. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis.
Uniprot IDO43915
Protein RefSeqNP_004460.1
mRNA RefSeqNM_004469

Reference

  1. Angiotensin II Type 1 Receptor (AT-1R) Expression Correlates with VEGF-A and VEGF-D Expression in Invasive Ductal Breast Cancer. A. Jethon et al., Pathol Oncol Res. 2012 Oct; 18(4): 867–873.

All prices plus VAT + possible delivery charges